SPRC Key Statistics, Chart & Performance
The current stock price of SPRC is 1.03 USD. In the past month the price decreased by -34.15%. In the past year, price decreased by -91.41%.
SPRC Technical Analysis
SPRC Financial Highlights
Over the last trailing twelve months SPRC reported a non-GAAP Earnings per Share(EPS) of -22.63. The EPS increased by 91.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SPRC Forecast & Estimates
SPRC Ownership
SPRC Latest News, Press Relases and Analysis
SPRC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.64 | 969.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.02 | 525.77B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.36B | ||
| PFE | PFIZER INC | 7.96 | 144.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.53 | 113.90B | ||
| ZTS | ZOETIS INC | 19.67 | 54.96B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 22.99B | ||
| VTRS | VIATRIS INC | 5.51 | 14.78B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.18 | 12.01B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.83B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.36B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.22B |
Related stock screener links
About SPRC
Company Profile
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Company Info
SCISPARC LTD
20 Raul Wallenberg Street, Tower A
TEL AVIV-YAFO IL
Employees: 3
Phone: 97236103100
SCISPARC LTD / SPRC FAQ
Can you describe the business of SCISPARC LTD?
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
What is the stock price of SCISPARC LTD today?
The current stock price of SPRC is 1.03 USD. The price decreased by -4.63% in the last trading session.
Does SCISPARC LTD pay dividends?
SPRC does not pay a dividend.
What is the ChartMill rating of SCISPARC LTD stock?
SPRC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists SPRC stock?
SPRC stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of SCISPARC LTD (SPRC)?
SCISPARC LTD (SPRC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.63).